← Back to Home

Beyond Lowering Triglycerides: Phase 3 Plozasiran Trials Point to Reduced Pancreatitis Risk

A once-quarterly RNA interference therapy substantially lowered triglycerides in two pivotal Phase 3 trials, while a pooled analysis also showed fewer acute pancreatitis events; however, the event counts, full safety data, and subgroup sizes have yet to be disclosed.

By SURL BioNews

The challenge of treating severe hypertriglyceridemia goes beyond elevated numbers on a laboratory report. When fat-rich lipoproteins accumulate in large quantities, patients may experience recurrent acute pancreatitis, bringing hospitalization, pain, and even the risk of death. Preliminary results from two pivotal Phase 3 trials announced by Arrowhead Pharmaceuticals now provide an important signal: substantial lipid lowering may also translate into fewer clinical events.

SHASTA-3 and SHASTA-4 are both global, randomized, double-blind, placebo-controlled studies. A total of approximately 750 adults with severe hypertriglyceridemia received 25 mg of plozasiran or placebo by subcutaneous injection once every three months, for a total of four doses. At month 12, median triglyceride reductions in the two trials were 79% and 81%, respectively, compared with a reduction of approximately 27% in the placebo groups. The company said both studies met their primary endpoints and all prespecified secondary endpoints.

Plozasiran is a small interfering RNA therapy designed to suppress the liver’s production of apolipoprotein C-III (APOC3). This protein slows the breakdown and clearance of triglyceride-rich particles; reducing its production effectively removes a brake from the metabolic pathway. Compared with taking medication every day or receiving more frequent injections, once-quarterly dosing may also reduce the burden of long-term treatment.

What truly takes these results beyond lipid lowering alone is the prespecified pooled analysis of the two trials. In the broad study population with triglycerides above 500 mg/dL, the plozasiran group had 78% fewer cumulative acute pancreatitis events than the placebo group. Analyses of both the “proportion of patients experiencing at least one pancreatitis event” and the “overall event rate” also reached statistical significance. The company further said that, in the highest-risk subgroup—with triglycerides above 880 mg/dL and a history of pancreatitis—events were reduced by 100% in the treatment group. However, the actual number of events in each group, the subgroup size, and confidence intervals have not yet been disclosed, so the “100%” figure cannot be directly interpreted as proof that pancreatitis was completely prevented.

Regarding safety, Arrowhead said adverse events during treatment were consistent with existing data, with no new safety signals observed. In prespecified subgroups, there was no significant difference in liver fat content compared with placebo, and no signals of allergic reactions or thrombocytopenia emerged. This information remains a topline summary released by the company. At the time, the clinical trial registry pages had not yet provided full results, so discontinuation rates, common adverse events, and outcomes across different patient populations could not yet be independently assessed.

Plozasiran has already been approved in multiple markets for the rarer and more severe familial chylomicronemia syndrome; these two trials extend its development to the broader population of patients with severe hypertriglyceridemia. The company plans to submit a supplemental new drug application in the United States by the end of 2026, with full data scheduled to be presented at the European Society of Cardiology annual meeting in late August. At that point, the absolute number of pancreatitis events, follow-up duration, and complete safety data will determine whether these findings represent merely an eye-catching relative reduction or clinical evidence strong enough to change treatment trade-offs.

References

  1. Arrowhead Pharmaceuticals
  2. Zacks Small Cap Research
  3. ClinicalTrials.gov
  4. ClinicalTrials.gov